"This renowned investor syndicate is a strong endorsement of our world-leading technology for glaucoma.”
Michel Lussier - Chairman of the Board of Directors
iSTAR Medical was founded in 2011 and is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma.
When ambition meets ambition
Glaucoma is the second leading cause of adult blindness globally affecting more than 92 million people worldwide and driven by an increase in intraocular pressure. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma. iSTAR Medical is setting new frontiers in MIGS treatment of glaucoma. The positive results achieved at the first-in-human trial validates the potential of MINIject in the supraciliary space as the next therapeutic option for glaucoma patients.
Together, we build a leading company
We are looking forward to help build iSTAR Medical to become the leading player in the MIGS field. The financing, support and expertise of a solid, specialized Life Science syndicate aims to empower the developments towards commercialization of MINIject.
The BVA (Belgian Venture Capital & Private Equity Association) presented the awards for Belgian companies showing a remarkable growth trajectory with the support of venture capital or investment funds. iSTAR Medical - developer of ophthalmic implants for glaucome patients - is the 'Venture Company of the year' 2020.